BUZZ-Vanda Pharmaceuticals rises after BLA for rare skin disease treatment** Shares of Vanda Pharmaceuticals VNDA.O rise 7.2% to $6.74
** Co submits Biologics License Application (BLA) for imsidolimab to treat generalized pustular psoriasis $(GPP)$, a rare and life-threatening inflammatory skin disease
** Says BLA supported by positive data from late-stage GEMINI-1 and GEMINI-2 trials showing rapid and sustained disease clearance with favorable safety profile
** Vanda requests priority review from FDA citing GPP as a rare orphan disease with significant unmet need; says potential FDA approval due as early as mid-2026
** VNDA stock up 30% YTD, as of last close
(Reporting by Tharuniyaa Lakshmi in Bengaluru)
((tharuniyaa@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments